Company Filing History:
3 out of 2,893 
2 out of 1,209 
2 out of 517 
Years Active: 2014-2024
Title: Innovations in Cancer Treatment: The Contributions of Jeffrey Engelman
Introduction
Jeffrey Engelman is a distinguished inventor based in Chestnut Hill, MA, known for his significant contributions to cancer research and treatment. With a total of three patents to his name, Engelman has advanced the field of pharmaceuticals, particularly in developing innovative therapeutic combinations aimed at treating complex proliferative diseases.
Latest Patents
Engelman’s latest patents showcase his commitment to addressing challenging medical conditions. One notable patent involves a pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor. This combination is designed for simultaneous or sequential administration and is applicable in treating proliferative diseases. The therapeutic efficacy of this combination highlights Engelman’s focus on innovative treatment methodologies.
Another significant patent focuses on methods for treating cancer that is resistant to ErbB therapeutics, especially in cases associated with activating MET gene mutations or gene amplification. This patent provides valuable methods for combining anti-ErbB and anti-MET therapeutics, which could potentially mitigate resistance in cancer treatment.
Career Highlights
Throughout his career, Jeffrey Engelman has been affiliated with prestigious institutions, including the General Hospital Corporation and Dana-Farber Cancer Institute Inc. His work at these notable organizations has been pivotal in translating research findings into practical therapeutic solutions, influencing advancements in oncology.
Collaborations
Engelman has collaborated with esteemed colleagues such as Pasi Antero Janne and Lewis C. Cantley. Together, they have contributed to groundbreaking research efforts that bridge the gap between laboratory findings and clinical applications, illuminating pathways for innovative cancer treatments.
Conclusion
Jeffrey Engelman’s contributions to the field of cancer treatment through his inventive patents showcase his dedication to medical innovation. By addressing critical challenges in cancer therapy, Engelman’s work continues to impact clinical practices and improve patient outcomes worldwide.